SMA screening with HorizonTM
With new treatments for spinal muscular atrophy (SMA), screening isn’t just knowledge. Carrier screening means informed decisions and the opportunity for earlier, more effective, treatment; it means the chance to change the course of a child’s life.
Register for our 25-minute webinar on September 13 and 15 and learn tips on how to offer prenatal genetic screening to your patients.
Learn about SMA and the need for screening through Lola’s story
Brady Camp
Father of Lola (born with SMA)
Find out how knowing their carrier status led to different outcomes in their two kids with SMA
Alyssa and Michiel learned that they were carriers of SMA after their daughter, Annabelle, was diagnosed at 2 months of age. When they became pregnant again with Annabelle’s younger brother Jude, knowing their SMA carrier status allowed them to plan for earlier diagnosis and treatment. Jude received his first treatment at 9 days old.
Register for our 25-minute webinar: How to Offer Prenatal Genetic Screening
Tuesday, September 13 | 8 AM PT / 11 AM ET
Thursday, September 15 | 1 PM PT / 4 PM ET
-
Alicia Orta, MPH, MS, CGCGenetic Counselor
Medical Science Liaison, Women’s Health, Natera -
Vivienne Souter, MDOB/GYN and Geneticist
Medical Director, Women’s Health, Natera
Learn More About Horizon
All carrier screening is not equal, and choosing the right test for your patients is critical. Traditional SMA screens1 miss ~60% of patients Horizon identifies as at-risk SMA carriers.2,3 Learn how Horizon leverages advanced technology and unmatched support to help you and your patients.
References
1Prior and Professional Practice Guidelines Committee. Genet Med. 2008;10:840–842.
2McAndrew et al. Am J Hum Genet. 1997;60(6):1411-1422.
3Westemeyer et al. Genet Med. 2020;22(8):1320-28.